Nurix
Director, Nonclinical Toxicology Operations
Brisbane, California, United States. Posted 2 months ago
The role
This person will drive the planning and execution of nonclinical safety and toxicology activities. They will manage CROs, budgets, and contracts while providing program-level project management for drug discovery projects from lead optimization through IND filing.
What you will do
- Partner with Toxicology Leads to scope, design, and schedule safety studies.
- Identify, qualify, and manage CROs and specialty vendors.
- Own the contract lifecycle including work orders, MSAs, and budget tracking.
- Build and maintain integrated study timelines and monitor milestones.
- Coordinate protocol and report review cycles.
- Track deliverables required for regulatory submissions.
- Ensure safety issues are communicated rapidly to leadership and agencies.
- Serve as project manager for discovery and development programs from lead optimization through IND filing.
- Develop integrated program plans spanning multiple scientific disciplines.
- Run project team meetings and maintain program dashboards and risk registers.
Required qualifications
- M.S. or Ph.D. in a life sciences discipline (toxicology, pharmacology, biology, chemistry, pharmaceutical sciences, or related)
- 10+ years of relevant biotech or pharmaceutical experience
- Demonstrable project management ownership of multidisciplinary programs
- Track record managing CROs and external vendors
- Direct experience supporting and coordinating IND-enabling activities
- Working knowledge of small molecule drug discovery and development, nonclinical safety assessment, and GLP requirements
- Proficiency with project management tools and methods
Nice to have
- formal project management credential such as PMP
- Experience in targeted protein degradation, oncology, or immunology
- Familiarity with AI tools
About the company
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company aims to establish degrader-based treatments at the forefront of patient care.